(616 Kb) 〈Recent - 2027〉

Explain the specific (toxicities) that led to these discontinuations. Compare these results to more recent ibrutinib studies .

: A major finding was that 41% of patients stopped taking ibrutinib within a median of 17 months. (616 KB)

: Finding ways to help patients manage side effects so they can stay on the therapy longer. Explain the specific (toxicities) that led to these

This article, available through PubMed Central (PMC) , provides a comprehensive look at how the drug performs in real-world clinical settings compared to controlled trials. Study Overview: The 616-Patient Cohort available through PubMed Central (PMC)

: Both groups had roughly the same time (about 85–87 months) from their initial diagnosis until they started ibrutinib treatment. Clinical Implications